ライフサイエンスコーパス: ibutilide

1 block cycle length similarly prolonged with ibutilide.

2 je system increased in 61% of patients after ibutilide.

3 /-SD) and were administered 2 mg intravenous ibutilide.

4 ned torsade de pointes (1 of 70, 1.4%) after ibutilide.

5 nus rhythm was enhanced by pretreatment with ibutilide.

6 on with or without pretreatment with 1 mg of ibutilide.

7 attempted again after the administration of ibutilide.

8 , for 0.005-, 0.010-, 0.015- and 0.025-mg/kg ibutilide.

9 and efficacy was dose related (placebo 15%; ibutilide 0.25 mg 40%, 0.5 mg 47%, and 1.0 mg 57%).

10 Effects of tadalafil (100 mg by mouth), ibutilide (0.002 mg/kg intravenously), and placebo on th

11 A low dose of ibutilide (0.003 mg/kg), infused intravenously for 10 mi

12 e patients received placebo and 159 received ibutilide (0.005 mg/kg [n = 41], 0.010 mg/kg [n = 40], 0

13 ecorded before, during and after intravenous ibutilide (0.005 to 0.025 mg/kg body weight, n = 25) or

14 inute infusions, separated by 10 minutes, of ibutilide (1.0 and 0.5 mg or 1.0 and 1.0 mg) or placebo.

15 ent) and in all 50 patients who had received ibutilide (100 percent, P<0.001).

16 After infusion of ibutilide (2 mg over 15 minutes), AFL cycle length (CL)

17 de 100 to 300 mg/day (n = 25), presented for ibutilide (2.0 mg) cardioversion.

18 ccurred in 2 of the 64 patients who received ibutilide (3 percent), both of whom had an ejection frac

19 ed in 36 of 50 patients who had not received ibutilide (72 percent) and in all 50 patients who had re

20 We examined the effect of ibutilide, a class III antiarrhythmic agent, on the ener

21 and safety of repeated doses of intravenous ibutilide, a class III antiarrhythmic drug, in terminati

22 at conversion of atrial flutter in humans by ibutilide, a new class III antiarrhythmic agent, is char

23 d 5- to 10-ms changes in corrected QT in the ibutilide active control group.

24 r incidence of adverse effects as the use of ibutilide alone.

25 A series of ibutilide analogues with fluorine substituents on the he

26 The conversion rate was 47% after ibutilide and 2% after placebo (P < .0001).

27 ent) or block multiple ionic channels (e.g., ibutilide and azimilide) in order to prolong atrial and

28 ical significance of the interaction between ibutilide and class IC agents is unknown.

29 In AF, ibutilide and procainamide induced similar increases in

30 terminated by atrial overdrive pacing after ibutilide at CLs equal to or longer than those that were

31 sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillati

32 Ibutilide caused transient loss of the delta wave in 1 p

33 Ibutilide causes prolongation of AFL CL and increased CL

34 Enhanced conversion efficacy of ibutilide compared with procainamide in AFL is correlate

35 The use of ibutilide converted 54% of patients with atrial flutter

36 Ibutilide converted atrial flutter in 14 of 25 patients

37 e length was prolonged to the same extent in ibutilide converters and nonconverters (36 +/- 19 vs. 38

38 The two ibutilide dosing regimens did not differ in conversion e

39 mpared with placebo, evidence was strong for ibutilide, flecainide, dofetilide, propafenone, amiodaro

40 he QT intervals were further prolonged after ibutilide for the group from 371+/-61 to 479+/-92 ms (P:

41 mall increase in corrected QT interval after ibutilide (from442 +/- 61 ms to 462 +/- 59 ms, p = 0.006

42 ntravenous dose of placebo or an infusion of ibutilide fumarate at 0.005, 0.010, 0.015 or 0.025 mg/kg

43 Ibutilide fumarate is an intravenous (IV) class III anti

44 Ibutilide fumarate is an investigational class III antia

45 was to determine the efficacy and safety of ibutilide fumarate, an approved drug for the rapid conve

46 ve either two 10-min IV infusions of 1 mg of ibutilide fumarate, separated by a 10-min infusion of 5%

47 usions of placebo or 0.25, 0.5, or 1.0 mg of ibutilide fumarate.

48 Intravenous ibutilide given in repeated doses is effective in rapidl

49 luated for efficacy: 35 (58.3%) of 60 in the ibutilide group compared with 11 (18.3%) of 60 in the pr

50 The placebo and 0.005-mg/kg ibutilide groups had lower success rates than all other

51 Similarly, in the atrial fibrillation group, ibutilide had a significantly higher success rate than p

52 In the patients with atrial flutter, ibutilide had a significantly higher success rate than p

53 The efficacy of ibutilide in conversion of atrial fibrillation and flutt

54 Our observations suggest that the use of ibutilide in patients receiving class IC agents is as su

55 We report the use of ibutilide in terminating AP-mediated AF, including the f

56 In AFL, ibutilide increased atrial monophasic action potential d

57 Ibutilide increased MAPD/CL ratio, whereas procainamide

58 increases in atrial CL (48% versus 45%), but ibutilide induced a greater increase in MAPD (52% versus

59 Attenuation of ibutilide-induced QT prolongation has been observed in a

60 e (r = 0.09), were inversely correlated with ibutilide-induced QT prolongation.

61 rdiogram at timed intervals during and after ibutilide infusion and standardized for variations in he

62 mean [SD]) millisecond increase in QTc after ibutilide infusion was greater for women during menses (

63 Ibutilide is a class III drug that is used for the cardi

64 Ibutilide is a useful and safe treatment alternative for

65 These data demonstrate that ibutilide is able to rapidly terminate atrial fibrillati

66 length, but conversion of atrial flutter by ibutilide is characterized by increased variability in a

67 PD than atrial CL, and termination of AFL by ibutilide is characterized by oscillations in atrial CL

68 Conversion of AF by ibutilide is enhanced by a longer baseline mean atrial C

69 Ibutilide may facilitate pace termination of AFL by deve

70 59) in 136 patients treated with intravenous ibutilide (n=73) or placebo (n=22) as participants in ra

71 flutter conversion and remained unchanged in ibutilide nonconverters and placebo group patients.

72 rhythmia was seen with the administration of ibutilide occurring at the end of infusion.

73 We prospectively evaluated the effects of ibutilide on the conduction system in patients with acce

74 Despite QT-interval prolongation after ibutilide, only 1 episode of torsade de pointes occurred

75 surements were made in patients who received ibutilide or placebo but did not convert.

76 s study establishes the superior efficacy of ibutilide over procainamide when administered to patient

77 ence of proarrhythmia did not correlate with ibutilide plasma concentration.

78 successful in a patient who had not received ibutilide pretreatment, ibutilide was administered and t

79 The conversion rates in AFL with ibutilide, procainamide, and placebo were 64% (29 of 45

80 Ibutilide prolonged refractoriness of the atrioventricul

81 Ibutilide prolonged the antegrade atrioventricular node

82 The selective class III antiarrhythmic agent ibutilide prolongs action potential duration and termina

83 Ibutilide prolongs atrial cycle length, but conversion o

84 Treatment with ibutilide resulted in significantly higher conversion ra

85 Ibutilide shortened and procainamide prolonged action po

86 ting atrial fibrillation and atrial flutter, ibutilide significantly reduces human atrial defibrillat

87 The active control, ibutilide, significantly increased QTcI by 6.9 and 8.9 m

88 Ibutilide terminated AF in 21 of 22 patients (95%) durin

89 In part I, we gave ibutilide to 22 patients (18 men, 31+/-13 years of age)

90 hERG block by close analogs of clofilium and ibutilide, to assess how specific alterations in drug st

91 s adverse effect and occurred in 1.8% of the ibutilide-treated patients compared with 1.2% of patient

92 The most frequent adverse events in ibutilide-treated patients were sustained and nonsustain

93 Of 180 ibutilide-treated patients, 15 (8.3%) developed polymorp

94 atients (95%); 32 (28%) required concomitant ibutilide treatment.

95 er study compared the efficacy and safety of ibutilide versus procainamide for conversion of recent-o

96 who had not received ibutilide pretreatment, ibutilide was administered and transthoracic cardioversi

97 Pretreatment with ibutilide was associated with a reduction in the mean en

98 Termination of AFL with ibutilide was characterized by significant increases in

99 In part II, ibutilide was given to 18 patients (14 men, 28+/-21 year

100 Ibutilide was significantly more effective in converting

101 The efficacy and safety of ibutilide were studied in 200 patients with atrial flutt

102 irty-nine patients who did not convert after ibutilide were treated with electrical cardioversion, an

103 One patient who received ibutilide, which was found to be a protocol violation, h

104 study compared the antiarrhythmic effects of ibutilide with the class IA agent procainamide in humans

105 nd sex differences exist in QTc responses to ibutilide, with the greatest increase in QTc correspondi